$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
Healthcare heavyweight Allergan has agreed to buy medical technology firm Zeltiq Aesthetics for almost $2.5 billion (£2 billion) in cash.
The deal gives Allergan control of Zeltiq’s CoolSculpting system, which uses targeted cooling to eliminate fat cells. The move adds to Allergan’s cosmetic and aesthetic treatment portfolio, which includes various applications of Botox (onabotulinumtoxin A) as well as double chin-reducing injection Kybella (deoxycholic acid).
The system has been cleared for marketing by the US Food and Drug Administration, but is not generally covered by medical insurance – users must pay for it privately.
As Business editor, Phillip's aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping them abreast of trends and developments in the world of chemistry businesses.View full profile
No comments yet